ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name Mentaily--- * Website------ https://www.linkedin.com/company/mentaily/
*
CEO name------ Iris Shtein
*
Select a CATEGORY: Health IT/Digital *
(Delete categories you are not selecting)

SESSIONS:
• War-Time Innovation, Peace-Time Solutions; Harnessing Crisis-Driven Breakthroughs for the Future of Medicine

Executive Summary / Investment Rationale

Mentaily is an AI-powered mental health platform transforming clinical triage and decision support. Developed at Sheba Medical Center in collaboration with Microsoft, it addresses global mental health workforce shortages and diagnostic inefficiencies. Backed by government agencies and Microsoft's Global Black Belt team, Mentaily has already launched pilots with national-scale partners and won multiple innovation grants. Led by a strong clinical and technological founding team.

Core Technology

Mentaily uses a proprietary multi-layered AI to analyze intake conversations and generate structured diagnostic insights. Its patented contextual agent mimics clinician logic, enabling faster, safer triage. Unlike chatbots, it supports—rather than replaces—clinical decisions, improving both patient flow and diagnostic accuracy across varied populations.

Product Profile / Pipeline

The flagship product supports screening, triage, and early detection for PTSD, depression, and anxiety in high-risk populations (e.g., veterans, trauma survivors, and teens). A successful pilot with 300 patients is underway. Expansion is planned in the U.S. via Brigham and Women's and McLean Hospitals. Pipeline includes additional psychiatric conditions and adolescent-focused modules.

Business Strategy

Mentaily offers a B2B SaaS model targeting healthcare systems, payers, and governments. Short-term revenue is driven by pilot implementations and per-screening fees; long-term growth comes from platform licensing, partnerships, and CPT reimbursement integration. Expansion starts in Israel, the U.S., and Australia.

What’s Next?

Clinical validation results will be published in 2025. Expansion pilots are planned in leading U.S. and Australian health systems. Regulatory approval (AMAR, FDA pathway) is in progress. Financial goals include completing a funding round to scale R&D, deploy globally, and finalize payer integration.